Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance.

Joint Bone Spine

Service de rhumatologie, hôpital Pellegrin, centre hospitalier universitaire de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux, France; Université de Bordeaux, 146, rue Léo-Saignat, 33076 Bordeaux, France. Electronic address:

Published: October 2018

Objective: To explore acceptance and retention rate of biosimilar CT-P13 after switching from originator infliximab (OI) in patients with various rheumatic diseases.

Methods: Patients with stable rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis (PsA) under OI were proposed to switch to CT-P13 at the same regimen. A prospective cohort of infliximab-naïve patients beginning CT-P13 and a retrospective cohort of patients treated with OI were used as controls. The primary outcome was to evaluate the retention rate of CT-P13. Secondary outcomes were the switch acceptance rate, reasons of failure and safety.

Results: Switch was proposed to 100 patients and accepted by 89 of them (63 AS, 12 PsA and 14 RA). After a median follow-up of 33 weeks, 72% of patients were still treated with CT-P13. This retention rate was significantly lower than the one found in our retrospective and prospective control cohorts: 88% and 90% respectively (P-value=0.0002). Within patients who asked to be reswitched to OI, 13/25 (52%) presented clinical disease activity, one developed serum sickness and 11 (44%) presented no objective activity. A subanalysis excluding these 11 patients abrogated difference in retention rates between the 3 cohorts (P-value=0.453). After reswitching to OI, patients without objective disease activity claimed to recover original efficacy.

Conclusions: Retention rate was lower after switching from OI to CT-P13 compared to our control cohorts. However, this difference faded after excluding patients without objective clinical activity, suggesting a reluctance of patients to the switch and a negative perception of the biosimilar.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbspin.2017.10.003DOI Listing

Publication Analysis

Top Keywords

retention rate
16
patients
11
switching originator
8
originator infliximab
8
biosimilar ct-p13
8
patients treated
8
rate lower
8
control cohorts
8
disease activity
8
excluding patients
8

Similar Publications

Effects of ultrasound-assisted low-salt curing on water retention, tenderness and in vitro digestive characteristics of grass carp (Ctenopharyngodon Idellus).

Ultrason Sonochem

December 2024

Hubei Key Laboratory of Edible Wild Plants Conservation & Utilization, College of Life Sciences, Hubei Normal University, Huangshi 435002, China; Hubei Engineering Research Center of Special Wild Vegetables Breeding and Comprehensive Utilization Technology, Hubei Normal University, Huangshi 435002, China. Electronic address:

The implementation of innovative techniques to achieve low-salt strategies in cured products is a critical issue faced by the food industry. This study aimed to investigate the impact of ultrasound treatment on the quality of the low-salt air-dried fish. The results showed that compared to traditional liquid curing, ultrasound-assisted curing significantly increased the NaCl transfer rate, improved tenderness, and improved water retention and in vitro digestibility (p < 0.

View Article and Find Full Text PDF

Method development and validation on RP-HPLC method for estimation of xanthohumol in nanostructured lipid carriers drug delivery systems.

J Chromatogr B Analyt Technol Biomed Life Sci

December 2024

School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia. Electronic address:

Xanthohumol(Xn) is isolated from female inflorescences of Humulus lupulus. It has been discovered that Xn and its formulation are useful in the treatment of cancer. As this bioactive compound has medicinal importance, hence, a novel, precise, and sensitive HPLC method should be developed.

View Article and Find Full Text PDF

High-Rate 4.2 V Solid-State Potassium Batteries by In Situ Polymerized Epoxide Ether Electrolyte.

Nano Lett

January 2025

College of Materials Science and Engineering, Hunan Joint International Laboratory of Advanced Materials and Technology of Clean Energy, Hunan Province Key Laboratory for Advanced Carbon Materials and Applied Technology, Hunan University, Changsha 410082, China.

Article Synopsis
  • Solid-state metallic potassium batteries (SSMPBs) are gaining attention as alternatives to lithium batteries, but face challenges like low ionic conductivity and high interfacial resistance.
  • Researchers achieved improved performance by using in situ ring-opening polymerization with a plasticizer and catalyst, resulting in short-chain polyether electrolytes that significantly enhance ionic conductivity.
  • The developed SSMPBs show a high discharge capacity of 69 mAh/g at 100 mA/g and 88.8% capacity retention after 100 cycles, outperforming previous SSMPB studies.
View Article and Find Full Text PDF

Autologous Fat Injection for Rhinoplasty: A Systematic Review of Satisfaction, Reinjection and Fat Retention.

Aesthetic Plast Surg

January 2025

Department of Plastic Surgery and Burns Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515051, Guangdong, China.

Background: Autologous fat injection has been proposed as a potential alternative to traditional rhinoplasty. However, the technique has been criticized for its disappointing retention and the potential complications associated with underfilling.

Objective: To summarize data on patient satisfaction, retention, complications and reinjection to provide a reference for fat injection for rhinoplasty.

View Article and Find Full Text PDF

Objective: Epilepsy is common among patients with severe motor and intellectual disability (SMID) patients, often taking a prolonged and intractable course. Lacosamide (LCM) is widely used to treat epilepsy in both adults and children. We assess the efficacy and tolerability of LCM among pediatric and young adult epilepsy patients with SMID who suffer from intractable seizures.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!